Gabelli reaffirmed their hold rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) in a report released on Friday morning.
Several other research analysts also recently commented on LXRX. Zacks Investment Research downgraded Lexicon Pharmaceuticals from a hold rating to a sell rating in a research note on Friday, July 27th. Needham & Company LLC reissued a hold rating on shares of Lexicon Pharmaceuticals in a research note on Monday, July 30th. Stifel Nicolaus reissued a buy rating and set a $23.00 target price (down previously from $24.00) on shares of Lexicon Pharmaceuticals in a research note on Tuesday, July 31st. BidaskClub downgraded Lexicon Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, July 31st. Finally, ValuEngine downgraded Lexicon Pharmaceuticals from a hold rating to a sell rating in a research note on Friday, August 17th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and three have assigned a buy rating to the company. The stock has a consensus rating of Hold and a consensus target price of $25.25.
Shares of NASDAQ LXRX traded up $0.14 during trading on Friday, hitting $8.93. The company had a trading volume of 2,230 shares, compared to its average volume of 427,683. The company has a quick ratio of 2.83, a current ratio of 2.90 and a debt-to-equity ratio of 8.85. Lexicon Pharmaceuticals has a 12 month low of $7.42 and a 12 month high of $13.97. The company has a market capitalization of $898.91 million, a P/E ratio of -7.06 and a beta of 0.73.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.07. Lexicon Pharmaceuticals had a negative return on equity of 1,247.65% and a negative net margin of 168.23%. The firm had revenue of $6.90 million for the quarter, compared to the consensus estimate of $12.56 million. During the same quarter last year, the company earned ($0.29) earnings per share. The business’s revenue for the quarter was down 74.3% compared to the same quarter last year. Research analysts anticipate that Lexicon Pharmaceuticals will post -1.38 EPS for the current year.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. First Trust Advisors LP bought a new stake in Lexicon Pharmaceuticals during the 3rd quarter valued at approximately $1,525,000. Bank of Montreal Can raised its stake in Lexicon Pharmaceuticals by 8,364.1% during the 3rd quarter. Bank of Montreal Can now owns 122,053 shares of the biopharmaceutical company’s stock valued at $1,302,000 after purchasing an additional 120,611 shares during the period. Northern Trust Corp raised its stake in Lexicon Pharmaceuticals by 2.1% during the 2nd quarter. Northern Trust Corp now owns 584,393 shares of the biopharmaceutical company’s stock valued at $7,013,000 after purchasing an additional 12,289 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in Lexicon Pharmaceuticals during the 2nd quarter valued at approximately $205,000. Finally, Tocqueville Asset Management L.P. bought a new stake in Lexicon Pharmaceuticals during the 2nd quarter valued at approximately $164,000.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Recommended Story: Understanding Price to Earnings Ratio (PE)
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.